Survival Outcomes Following Combination of First-Line Platinum-Based Chemotherapy with S-1 in Patients with Advanced Gastric Cancer

Abstract

The efficacy of S-1 combined with a platinum agent in the first-line setting and in patients with advanced gastric adenocarcinoma has been previously demonstrated in randomized clinical trials. However, real-world data regarding S-1 efficacy in European patients remains limited. In the present study, we reviewed the data of a European cohort of patients with advanced gastric cancer treated with first-line therapy consisting of S-1 in combination with a platinum agent. Forty-eight patients (29 with locally advanced/inoperable and 19 with metastatic disease) were treated with S-1 plus oxaliplatin (33 patients) or S1 plus cisplatin (15 patients). The Cox regression analysis, adjusted with propensity score, indicated that the use of cisplatin as compared to oxaliplatin was associated with increased risk of death (HR 9.634, p = 0.000). Four SAEs (serious adverse events) GIII were recorded (1 fatigue, 1 neutropenia, 1 anemia, 1 diarrhea) in 3 patients. S-1 combination with a platinum agent in the first-line setting in European patients with advanced gastric cancer results to similar survival outcomes and toxicity with previously reported data from Asian populations. S-1 combination with oxaliplatin seems to be associated with superior efficacy as compared to cisplatin.

Docetaxel, Oxaliplatin with Capecitabine (TEX Regimen) in Metastatic Gastric and Gastroesophageal Adenocarcinoma: A Prospective Single-Arm Observational Study from a Tertiary Cancer Center in Kashmir

“…The selection is based on patient performance status, general health, comorbid illnesses, and patient preference. 22 Docetaxel-based triplet regimens for advanced gastric cancer have become more common following the results of the V-325 trial of Van Cutsem et al 2006, which concluded that the use of DCF resulted in improved clinical outcomes and survival compared with only CF regimen, 14 but with higher frequency of adverse events (82% severe neutropenia, A Prospective Observational Study of TEX Regimen in Metastatic Gastric and Gastroesophageal Adenocarcinoma Puthiyottil et al…”

LINC01088 regulates the miR-95/LATS2 pathway through the ceRNA mechanism to inhibit the growth, invasion and migration of gastric cancer cells

“…14 The effects of traditional adjuvant treatment measures such as chemotherapy and radiotherapy are also limited. 15,16 Some targeted medications and immunological drugs, such as programmed death 1 (PD-1) and programmed cell death ligand 1 (PD-L1), have recently been used in clinical trials to treat GC, with promising results, [17][18][19] but the comprehensive treatment effect is still not satisfactory. Therefore, the screening and identification of novel molecules closely related to GC progression significantly improve clinical treatment effects.…”